Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study

Next Previous
Trial Profile

A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ropeginterferon alfa-2b (Primary) ; Anagrelide
  • Indications Essential thrombocythaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SURPASS ET
  • Sponsors PharmaEssentia Corporation

Most Recent Events

  • 31 Aug 2026 According to a PharmaEssentia Corporation media release, company announced the U.S. Food and Drug Administration (FDA) has approved BESREMi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET).
  • 10 Jun 2026 According to a PharmaEssentia Corporation media release, company has announced that the Taiwans Ministry of Health and Welfare (MOHW) has approved ropeginterferon alfa-2b-njft (BESREMi) for the treatment of adult patients with essential thrombocythemia (ET). BESREMi is the first new therapy approved for ET in nearly 30 years.
  • 22 May 2026 According to a PharmaEssentia Corporation media release, the data from the trial will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2026 Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top